Introduction
In the end of 2019, early of 2020 unknown pneumonia caused very contagious pathogen was reported at Wuhan City, Hubei province, China. Novel corona virus in respiratory specimens was detected by next generation sequencing or real-time RT-PCR methods.1Chinese scientist released the complete sequenced of the novel corona virus (WH-Human_1) on January 10, 2020 and it is freely online available in the Gene Bank.2 (ICTV) International Committee on Taxonomy of Viruses named the virus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Later on, the World Health Organization (WHO) was official named the novel coronavirus as COVID-19. There are four type of corona virus: α-coronavirus (α-COV), β-coronavirus (β-COV), δ-coronavirus (δ-COV) and γ - coronavirus (γ-COV). This novel coronavirus (COVID-19) is belong to β-coronavirus, which is the most cosmopolitan virus in nature. Coronavirus is an RNA virus with single strand and about 80-120 nm in diameter.3 Before the end of 2019, there were 6 known coronavirus infect human and cause respiratory diseases. Of those six corona virus 229E, OC43, NL63,HKU, SARS‐CoV-1 and MERS‐CoV; SARS-Co-V-2 (COVID-19) became the seventh human corona virus and globally pandemic in 2020.4 The genomic sequence analysis of the novel corona virus revealed that the genomic sequence similarity shared with bat SARS coronavirus (SARSr-CoV-RaTG13) 96% 5 and SARS-CoV-1 (about 79%) and MERS-CoV (about 50%). Bat may be an important natural reservoir of the virus. Moreover, Phylogenetic analysis and homology modelling revealed that COVID-19 had a similar receptor-binding domain structure to that of SARS-CoV-1, despite amino acid variation at some key residues.6,7 The infectivity and transmission rate of COVID-19 is higher than that of SARS and MRES coronavirus indeed its mortality rate is unknown yet.8
Human beings are confronting a pandemic in COVID-19, due to the reason that the virus is new human pathogen so far there are no licensed vaccines or antibodies. Convalescence serum based therapy from fully recovered COVID-19 patient is one of the best option for immediate therapy. In China, at Wuhan the convalescent serum able to recovered 70% against COVID-19 patients. A scientific study from the previous outbreak of SARS-COV-1 enzyme‐linked immunosorbent assay (ELISA) and Western blot neutralization assay results confirmed that the anti‐SARS antibodies taken from the convalescent serum enabled neutralized the virus.9 The genomic sequence result indicated that this new virus (SARS-COV-2) shared the same receptors with the pervious SARS-COV-1) virus.6 Thus identify the receptor cells and produce monoclonal antibody against COVID-19 is important. In recent years, technology of monoclonal antibody become a powerful tool in diagnostic and therapeutic of various human Cancer and virus including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) and more recently novel coronavirus or SARS-CoV-2).10 11The relationship between the ABO Blood group and the COVID-19 susceptibility was reported.12 This has relationship with the antibody found in plasma, which indicated that the natural antibody found in the blood plasma could inhibit the interaction of the virus to its host receptor cell entry gate.13 In this article, we suggests that convalescent serum from fully recovered COVID-19 patients as an immediate therapy can aligned with ABO blood group COVID-19 non-susceptible ( lower risk) individuals. Most importantly, identify the immunogenic parts of the new pathogen (COVID-19) would lead to produce effective monoclonal antibody and vaccine.